MyMedx reported third-quarter 2026 net sales of $62 million, down 45% from the prior year period. Surgical sales rose 9% to $40 million, while wound sales fell 71% to $22 million. The FTC issued a second request that extends the Hart-Scott-Rodino waiting period for the pending Scenera MedTech acquisition.
MDXG · Mimedx Group, Inc.
10 customers — 22% of revenue (the year ended December 31, 2025)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2025)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
10 customers — 20% of revenue (the year ended December 31, 2024)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2024)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
10 customers — 20% of revenue (the year ended December 31, 2023)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 2% of revenue (the year ended December 31, 2023)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $3.11
- Open
- $3.18
- Day range
- $3.07–3.28
- 52-week closing range
- $3.09–7.25
- Average volume, 30 days
- 1.7M
- Short interest
- 9.0M · 6.1% of shares · 4.4 days
- Short volume, last session
- 50%
- Last earnings
- Oct 28, 2026
- Latest filing
- 10-Q · Oct 28
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
MiMedx reported third-quarter 2026 net sales of $62 million, compared to $114 million for the three months ended September 30, 2025, a decrease of 45%. It swung to a net loss of $9 million from net income of $17 million a year earlier. For 2026 it expects net sales of $250 to $260 million, and a patent license will pay $25 million in five installments.
Net sales were $62.3 million for the three months ended September 30, 2026, a decrease of 45.2%, with Wound sales down 71.0% on Medicare reimbursement changes. The company reported a GAAP net loss of $9 million, or $0.06 per diluted share. On October 15, 2026, the company and Sanara each received an FTC Second Request, extending the HSR waiting period for the pending acquisition.
MiMedx Group, Inc. and Sanara MedTech Inc. each received a Second Request from the Federal Trade Commission on October 15, 2026 in connection with the FTC's review of their pending merger, extending the HSR Act waiting period.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. MIMEDX reported Q2 net sales of $64 million, down 35% year-over-year on Medicare reimbursement headwinds in Wound, but delivered 9% sequential growth, 15% Surgical growth, and a $300 million-funded acquisition of Sanara MedTech that targets combined 2027 revenue above $400 million and adjusted EBITDA margin above 20%.
- + Surgical revenue grew 15% year-over-year in Q2 2026
- + Sequential revenue grew 9% with each month improving and June at $24 million
- + Wound care center unit volume grew 44% sequentially and 22% overall sequentially
- + Announced acquisition of Sanara MedTech with expected combined 2027 revenue well in excess of $400 million and adjusted EBITDA margin above 20%
- + Secured committed $300 million term loan financing for the Sanara acquisition
- + Submitted first two 510(k) applications, expanding regulatory pathway for placental and antimicrobial products
- − Q2 net sales declined 35% year-over-year due to Medicare reimbursement changes
- − Wound sales fell 61% year-over-year to $25 million
- − GAAP net loss of $15 million versus $10 million net income in the prior-year quarter
- − Adjusted EBITDA was a loss of $8 million (negative 13% margin) versus positive $24 million a year ago
- − Gross margin contracted to 69% from 81% on Wound pricing pressure
- − CMS proposed 2027 physician fee schedule indicates the current $127.14/sq. cm. skin substitute rate will remain, prolonging reimbursement pressure
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDXG
this stock
Mimedx Group, Inc.
|
$453.83M | -54.1% | +20.0% | — | 6.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 28, 2026
- This year
- 18
MiMedx reported third-quarter 2026 net sales of $62 million, compared to $114 million for the three months ended September 30, 2025, a decrease of 45%. It swung to a net loss of $9 million from net income of $17 million a year earlier. For 2026 it expects net sales of $250 to $260 million, and a patent license will pay $25 million in five installments.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDXG | -4.0% | -20.9% | -13.1% | -19.9% | -54.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +1.4% | -14.6% | -7.5% | -14.6% | -59.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.